The Global Nusinersen Market was valued at USD 1.71 Billion in 2024 and is projected to reach USD 2.46 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period (2025–2032). This growth is being driven by increasing SMA diagnosis rates, expanded newborn screening programs, and improved healthcare access in emerging economies.

As the SMA treatment landscape evolves toward precision medicine and early intervention, the spotlight is on the key pharmaceutical innovators who are driving clinical advancements, patient access initiatives, and therapeutic breakthroughs. In this blog, we profile the Top 10 Companies in the Nusinersen Industry—a mix of biotech leaders, antisense pioneers, and gene therapy developers shaping the future of spinal muscular atrophy care.

---

🔟 1. Neurocrine Biosciences

Headquarters: San Diego, California, USA
Key Offering: Pipeline SMA candidates, adjunctive therapies

Neurocrine Biosciences is advancing novel mechanisms for neuromuscular disorders, including investigational treatments that complement existing SMA therapies like nusinersen. Their research focuses on small molecule modulators to enhance motor neuron function, supporting comprehensive SMA management strategies.

Clinical Initiatives:

• Pipeline development for SMA adjunct therapies
• Collaborations on combination treatment regimens
• Focus on long-term patient outcome improvements

Download FREE Sample Report: Nusinersen Market – View in Detailed Research Report

---

9️⃣ 2. Cytokinetics, Inc.

Headquarters: South San Francisco, California, USA
Key Offering: Adjunctive SMA therapies, muscle modulators

Cytokinetics develops therapies targeting muscle function in neuromuscular diseases, positioning their candidates as potential complements to nusinersen in SMA treatment protocols. Their work emphasizes improving mobility and strength in pediatric and adult patients.

Clinical Initiatives:

• Research into cardiac-muscle synergies for SMA
• Clinical trials exploring multi-target approaches

---

8️⃣ 3. Scholar Rock

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Novel SMA mechanisms, myostatin inhibitors

Scholar Rock investigates proprietary mechanisms to enhance muscle growth in SMA, offering potential next-generation options alongside established therapies like nusinersen. Their targeted biologics aim to address unmet needs in later-stage SMA.

Clinical Initiatives:

• Ongoing Phase 3 trials in SMA Type II/III
• Partnerships for expanded patient access

---

7️⃣ 4. Genentech (Roche Subsidiary)

Headquarters: South San Francisco, California, USA
Key Offering: SMA research advancements, risdiplam support

Genentech, a Roche company, advances SMA therapies through innovative oral small molecules like risdiplam, competing in the nusinersen landscape while expanding treatment options for all SMA types.

Clinical Initiatives:

• Broad clinical data across SMA spectrum
• Global access programs in emerging markets

Download FREE Sample Report: Nusinersen Market – View in Detailed Research Report

---

6️⃣ 5. AveXis (Novartis Subsidiary)

Headquarters: Bannockburn, Illinois, USA
Key Offering: Gene therapies like Zolgensma for SMA

AveXis specializes in one-time gene therapies for SMA, providing curative potential that intersects with ongoing treatments such as nusinersen, particularly for early-onset cases.

Clinical Initiatives:

• Long-term follow-up studies on gene therapy outcomes
• Expanded newborn screening partnerships

---

5️⃣ 6. Ionis Pharmaceuticals

Headquarters: Carlsbad, California, USA
Key Offering: Antisense technology platform, nusinersen originator

Ionis, the original developer of nusinersen technology, leads in antisense oligonucleotides for rare diseases, licensing Spinraza to Biogen while advancing next-gen candidates.

Clinical Initiatives:

• Over 50 antisense programs in pipeline
• Expanded applications beyond SMA

---

4️⃣ 7. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Zolgensma gene therapy, SMA treatment portfolio

Novartis captures significant share through Zolgensma, a one-time infusion therapy for SMA, influencing the competitive dynamics around nusinersen adoption.

Clinical Initiatives:

• 15% share of new patient starts in key markets
• Risk-sharing reimbursement models

---

3️⃣ 8. Roche Holdings AG

Headquarters: Basel, Switzerland
Key Offering: Evrysdi (risdiplam) oral SMA therapy

Roche’s Evrysdi offers a convenient oral alternative for SMA patients across ages, gaining acceptance particularly for adults and those preferring non-intrathecal options.

Clinical Initiatives:

• Awareness campaigns and genetic testing partnerships
• Outcomes-based payer agreements

---

2️⃣ 9. Biogen Inc.

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Spinraza (nusinersen), SMA market leader

Biogen dominates with Spinraza, holding over 95% market share through first-mover advantage, global distribution, and proven efficacy data across SMA types.

Clinical Initiatives:

• Newborn screening program expansions
• Pricing reforms and compassionate access

Download FREE Sample Report: Nusinersen Market – View in Detailed Research Report

---

1️⃣ 10. Ionis Pharmaceuticals & Biogen Collaboration

Headquarters: Carlsbad, California, USA / Cambridge, Massachusetts, USA
Key Offering: Spinraza (nusinersen) antisense therapy

The Ionis-Biogen partnership delivers Spinraza, the foundational therapy for SMA via intrathecal administration, transforming outcomes for thousands worldwide with sustained motor improvements.

Clinical Initiatives:

• Label expansions to presymptomatic patients
• Global regulatory approvals including China and Brazil

Read Full Report: Nusinersen Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Nusinersen Treatment Is Precise and Accessible

The nusinersen market is undergoing a transformative shift. While antisense therapy maintains dominance through proven safety, the industry invests heavily in combination approaches, improved delivery, and global access programs.

📈 Key Trends Shaping the Market:

• Rapid newborn screening expansion in US and Europe
• Regulatory approvals driving Asia-Pacific growth at 5.8% CAGR
• Next-gen delivery systems and combination therapies
• Strategic payer partnerships for cost management

Read Full Report: Nusinersen Market – View in Detailed Research Report

The companies listed above are not only advancing SMA care—they’re spearheading the precision medicine era for neuromuscular disorders.